The insulin degludec press room provides in-depth information about insulin degludec and insulin degludec / insulin aspart, currently in development and includes previous company announcements, animations depicting the novel mechanism of protraction of these compounds as well as background and supporting information.
Take a look back at Novo Nordisk company announcements and press releases on developments for insulin degludec and insulin degludec / insulin aspart.
Download key background information on diabetes, diabetes treatment, and the insulin degludec and insulin degludec / insulin aspart clinical development programme.
Download photos from insulin degludec R&D and of the insulin degludec molecule.
Get the answers to frequently asked questions about insulin degludec and insulin degludec / insulin aspart.
Get a list of relevant links to dig deeper into the areas related to diabetes and insulin degludec.
Insulin degludec is an ultra-long-acting basal insulin being developed by Novo Nordisk. Insulin degludec and insulin degludec / insulin aspart have been submitted to regulatory authorities for review but have not yet been approved for use.
APROM ID# 4045. Date of Approval: May 2012